เว็บไซต์คืออะไร?

https://www.facebook.com/1191639804029397/

Cerberus Research Labs

Veteran-owned research and education company covering human biology, applied science, and emerging technology. Evidence over hype. US → Bangkok

Independent analysis for people who read the studies.

25/08/2026

🇺🇸🇹🇭This Week In Peptides:

We will be doing these weekly. We’ll be talking about what’s actually happening in the world of peptide research, not influencer, hyped-up BS. I’m in SE Asia. I meet the manufacturers. Things move faster here in the “peptide” world.

• STORY1:

🧬 Retatrutide continues to generate significant clinical interest as researchers study its triple-agonist mechanism and expanding clinical data. We know it’s the best fat loss drug ever created, but now a cancer cure? Maybe…

• STORY 2:

🔬 BPC-157 is also getting more attention as researchers dig deeper into mechanisms involving angiogenesis, nitric oxide pathways, gut-brain axis, and the almost “super-human” healing ability when combined with other compounds like RAD-140.

But this is the part that matters to me:

Research moves fast. Hype moves faster.

I want CRL to be a place where researchers can come for the information, the science, and eventually the materials without all the bu****it that surrounds this industry.

I’m a USMC combat veteran, an American business owner, and I’m based in Bangkok.

That puts me closer to the suppliers and manufacturers we work with.

Less distance.
Fewer layers.
Better communication.
More control over what we source. 🔬

No miracle claims. No pretending we know more than the research shows.

Just better information, better sourcing, and a commitment to doing things right.

🧪 Research first. Always.

Follow along for This Week in Peptides, research updates, new developments, and the science worth paying attention to.

For research use only. Not for human or veterinary use.

23/08/2026

🧠 SEMAX + SELANK. Two peptides. Two different pathways.

This is exactly why the combination keeps coming up in nootropic research discussions.

🔴 SEMAX is primarily studied around neurotrophic signaling, neuroplasticity, cognition, and dopaminergic pathways.

🔵 SELANK is studied around GABAergic signaling, stress-related pathways, and neurotransmitter modulation.

So the theory is pretty interesting: one side of the stack is investigating cognitive and neurotrophic signaling, while the other is investigating stress regulation. That makes the combination mechanistically interesting.

But here’s where we separate research from hype. 🔬

There isn’t strong clinical evidence proving that Semax + Selank together are superior to either compound individually. That’s exactly the kind of distinction researchers should pay attention to. Interesting mechanism ≠ proven outcome.

And that’s the conversation we’re going to keep having here.

No hype. No miracle claims. Just the science, the research, and what we actually know.

🔬 For research use only. Not for human or veterinary use.

Semax and Selank are among the faster-growing nootropic-peptide topics in 2026, with recent creator-data analysis showing substantial growth in discussion around both compounds.

22/08/2026

THE COMPOUND IS ONLY PART OF THE RESEARCH. 🧪

Good research starts long before anything goes under the microscope.

How was the material handled?
How was it stored?
What information came with it?
Can you actually track what you’re working with?

Those details matter.

At Cerberus Research Labs, we’re focused on building a research supply system around consistency, documentation, organization, and accessibility.

Because serious researchers don’t need more noise.

They need better inputs.

That’s what we’re building.

🧬 www.cerberusresearchlabs.com

🐺 CERBERUS RESEARCH LABS

For research use only. Not for human or veterinary use.

21/08/2026

🧪 One good batch isn’t enough.

Anyone can have a product that looks good once.

Serious research requires consistency from batch to batch. 🔬

That means paying attention to how materials are sourced, tested, documented, packaged, and handled before they ever reach the researcher.

At Cerberus Research Labs, our standard is simple:

🔬 Quality-focused sourcing
🧪 Batch testing
📄 Documentation available
📦 Professional packaging
🚚 Reliable fulfillment
🤝 Responsive support

Because when your research depends on consistency, “close enough” isn’t good enough.

⚔️ Precision. Purity. Research Integrity.

🔬 For research use only. Not for human or veterinary use.

15/08/2026

🌎 Your research shouldn’t be limited by geography.

Cerberus Research Labs provides a streamlined way for qualified researchers to source research-use-only materials internationally. 🔬

📦 Worldwide shipping
🔒 Discreet, professional packaging
✈️ International fulfillment
📄 Documentation available upon request
🇺🇸 American-run from Asia
⚔️ Veteran owned and operated

We understand the challenge of working with overseas suppliers. Different time zones. Language barriers. Unclear shipping. Complicated communication.

Our goal is simple:

Make the process cleaner. Make communication easier. Keep research moving.

🌎 Global reach. Lab-focused.

🔬 For research use only. Not for human or veterinary use.

09/08/2026

🦂 What if a scorpion’s venom could help surgeons see a tumor?

Sounds like science fiction. It isn’t.

The deathstalker scorpion produces a short peptide called chlorotoxin. Researchers discovered that it can preferentially bind to tumor cells, creating a fascinating targeting mechanism.

Attach a fluorescent marker, and researchers can make tumor tissue light up while surrounding healthy tissue stays dark. 🔬

That concept became known as “Tumor Paint.”

The science is still being studied, but the underlying targeting mechanism is one of the most fascinating examples of how venom can become a starting point for modern biomedical research.

A scorpion built to kill.
A peptide researchers are studying to help visualize what surgeons couldn’t easily see.

The literature is public. The science is fascinating.

⚠️ For research use only. Not for human or veterinary use.

05/08/2026

🐍 A snake bite that crashes blood pressure became a pill.

🌿 Deep in the Brazilian rainforest lives the Brazilian pit viper (Bothrops jararaca). Its venom contains short peptides that cause blood pressure to collapse, making it easier for prey to stop running.

🔬 In the 1960s, researcher Sérgio Ferreira uncovered why. These venom peptides block angiotensin-converting enzyme (ACE), an enzyme that helps blood vessels tighten.

💡 To the snake, it was a weapon. To medicinal chemists, it was a blueprint.

💊 Researchers at Squibb used that discovery to design captopril, a small molecule inspired by those venom peptides. Approved in 1981, it became the first ACE inhibitor, launching an entirely new class of medicines.

🧬 Same biological pathway. Opposite purpose.

📚 Sometimes the biggest breakthroughs don’t come from inventing something new. They come from understanding what nature already built.

⚠️ For research use only. Not for human or veterinary use.

03/08/2026

🦎 The biggest drug class in the world started as venom.

🧬 Every time you eat, your body releases GLP-1. The problem? An enzyme called DPP-4 destroys it in about two minutes, making native GLP-1 a poor drug candidate.

🔬 In 1992, Dr. John Eng isolated a peptide from Gila monster venom called Exendin-4. While it’s only about 53% identical to human GLP-1, one critical amino acid is different.

⚡ That single substitution prevents DPP-4 from cutting the peptide. It activates the same receptor but survives dramatically longer.

💡 That discovery led to the first approved GLP-1 receptor agonist in 2005, and every long-acting GLP-1 therapy since has been built around solving the same stability problem with different chemistry.

🧪 Sometimes, one amino acid changes everything.

📚 Eng et al., Journal of Biological Chemistry, 1992.

⚠️ For research use only. Not for human or veterinary use.

02/08/2026

💰 $30 or $300? 🤷

🧪 Same compound. Same milligrams on the label. Sometimes even the same source laboratory.

So why the massive price difference?

At Cerberus Research Labs, we don’t pay for hype. We pay for quality. 🔬

Here’s where that investment goes:

🧪 Purification
Every purification pass removes failed peptide sequences and unwanted byproducts. Higher purity means lower yield, which makes every successful batch more expensive.

📊 Independent Testing
Every lot is verified with HPLC and Mass Spectrometry. Independent analytical testing isn’t cheap, but it’s one of the first corners low-cost suppliers cut.

⚖️ Purity ≠ Peptide Content
This is where many buyers get misled. A vial can show 99% purity and still contain significantly less actual peptide by weight because water, salts, and counterions aren’t reflected in that purity percentage.

📄 That’s why Cerberus Research Labs values complete documentation.
A quality Certificate of Analysis reports both purity and peptide content, giving researchers a much clearer picture of what’s actually in the vial.

🎯 The lowest price rarely reflects the highest standard. When research matters, documentation, analytical testing, and manufacturing quality matter too.

🧬 Precision. Purity. Research Integrity.

⚠️ For research use only. Not for human or veterinary use.

01/08/2026

🧪 99% pure.

❓ 99% of what?

📊 That number comes from a chromatogram. It compares the target peptide peak to the other peptide peaks, telling you that nearly all of the detected peptide is the correct sequence. That’s valuable information.

⚠️ But here’s what it doesn’t measure.

💧 Water. 🧂 Salts. 🧪 Residual purification acids. If it isn’t detected as a peptide peak, it doesn’t contribute to that 99%.

⚖️ That’s where peptide content comes in.

🔬 Peptide content measures how much of the powder is actually peptide by mass, typically determined using amino acid analysis. For many salt forms, that value commonly falls around 70–90%.

🎯 Both numbers can be completely accurate. They simply answer different questions.

📄 If a Certificate of Analysis only reports one of them, you’re looking at a percentage without the full picture.

⚠️ For research use only. Not for human or veterinary use.